The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial

Rationale and design

Toshio Ogihara, Masunori Matsuzaki, Hiroaki Matsuoka, Kazuaki Shimamoto, Kazuyuki Shimada, Hiromi Rakugi, Seiji Umemoto, Akira Kamiya, Norihiro Suzuki, Hiroo Kumagai, Yasuo Ohashi, Shuichi Takishita, Keishi Abe, Takao Saruta, K. Kikuchi, S. Itoh, H. Suzuki, T. Fujita, J. Higaki, T. Etoh & 14 others C. Tei, S. Nogawa, T. Yoshikawa, K. Yumura, K. Utsunomiya, K. Kario, K. Kitagawa, H. Makino, M. Matsumoto, K. Hayashi, M. Kawana, M. Fujishima, K. Otsuka, K. Tanabe

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

A number of major clinical trials have demonstrated the clinical benefits of lowering blood pressure and have indicated that a majority of patients with hypertension will require more than one drug to achieve optimal blood pressure control. However, there is little data showing which antihypertensive combination best protects patients from cardiovascular events and which best achieves the target blood pressure with the fewest adverse events. The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial is the first large-scale investigator-initiated multicenter study with a prospective, randomized, open, blinded endpoint evaluation (PROBE) design to directly compare cardiovascular mortality and morbidity, incidence of adverse drug reaction, and degree of blood pressure reduction in Japanese hypertensive patients for a combination of angiotensin receptor blockers, β-blockers or thiazide diuretics in addition to a calcium antagonist, benidipine hydrochloride, with a response-dependent dose titration scheme. The COPE trial is being conducted with the cooperation of more than 100 centers and clinics in Japan and involves 3,000 patients, who will be followed for 3 years. Eligible patients are being enrolled from May 2003 until May 2006. Results from the COPE trial should provide new evidence for selecting optimal combination therapies for hypertensive patients.

Original languageEnglish
Pages (from-to)331-338
Number of pages8
JournalHypertension Research
Volume28
Issue number4
DOIs
Publication statusPublished - 2005 Apr

Fingerprint

Hypertension
Blood Pressure
Therapeutics
Sodium Chloride Symporter Inhibitors
Angiotensin Receptor Antagonists
Drug-Related Side Effects and Adverse Reactions
Antihypertensive Agents
Multicenter Studies
N-succinyl-1,2-dioleoylphosphatidylethanolamine
Japan
Research Personnel
Clinical Trials
Calcium
Morbidity
Mortality
Incidence
Pharmaceutical Preparations

Keywords

  • Benidipine
  • Combination therapy
  • Hypertension
  • Multicenter clinical trial
  • PROBE (prospestive, randomized, open, blinded endpoint evaluation)

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Ogihara, T., Matsuzaki, M., Matsuoka, H., Shimamoto, K., Shimada, K., Rakugi, H., ... Tanabe, K. (2005). The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial: Rationale and design. Hypertension Research, 28(4), 331-338. https://doi.org/10.1291/hypres.28.331

The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial : Rationale and design. / Ogihara, Toshio; Matsuzaki, Masunori; Matsuoka, Hiroaki; Shimamoto, Kazuaki; Shimada, Kazuyuki; Rakugi, Hiromi; Umemoto, Seiji; Kamiya, Akira; Suzuki, Norihiro; Kumagai, Hiroo; Ohashi, Yasuo; Takishita, Shuichi; Abe, Keishi; Saruta, Takao; Kikuchi, K.; Itoh, S.; Suzuki, H.; Fujita, T.; Higaki, J.; Etoh, T.; Tei, C.; Nogawa, S.; Yoshikawa, T.; Yumura, K.; Utsunomiya, K.; Kario, K.; Kitagawa, K.; Makino, H.; Matsumoto, M.; Hayashi, K.; Kawana, M.; Fujishima, M.; Otsuka, K.; Tanabe, K.

In: Hypertension Research, Vol. 28, No. 4, 04.2005, p. 331-338.

Research output: Contribution to journalArticle

Ogihara, T, Matsuzaki, M, Matsuoka, H, Shimamoto, K, Shimada, K, Rakugi, H, Umemoto, S, Kamiya, A, Suzuki, N, Kumagai, H, Ohashi, Y, Takishita, S, Abe, K, Saruta, T, Kikuchi, K, Itoh, S, Suzuki, H, Fujita, T, Higaki, J, Etoh, T, Tei, C, Nogawa, S, Yoshikawa, T, Yumura, K, Utsunomiya, K, Kario, K, Kitagawa, K, Makino, H, Matsumoto, M, Hayashi, K, Kawana, M, Fujishima, M, Otsuka, K & Tanabe, K 2005, 'The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial: Rationale and design', Hypertension Research, vol. 28, no. 4, pp. 331-338. https://doi.org/10.1291/hypres.28.331
Ogihara, Toshio ; Matsuzaki, Masunori ; Matsuoka, Hiroaki ; Shimamoto, Kazuaki ; Shimada, Kazuyuki ; Rakugi, Hiromi ; Umemoto, Seiji ; Kamiya, Akira ; Suzuki, Norihiro ; Kumagai, Hiroo ; Ohashi, Yasuo ; Takishita, Shuichi ; Abe, Keishi ; Saruta, Takao ; Kikuchi, K. ; Itoh, S. ; Suzuki, H. ; Fujita, T. ; Higaki, J. ; Etoh, T. ; Tei, C. ; Nogawa, S. ; Yoshikawa, T. ; Yumura, K. ; Utsunomiya, K. ; Kario, K. ; Kitagawa, K. ; Makino, H. ; Matsumoto, M. ; Hayashi, K. ; Kawana, M. ; Fujishima, M. ; Otsuka, K. ; Tanabe, K. / The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial : Rationale and design. In: Hypertension Research. 2005 ; Vol. 28, No. 4. pp. 331-338.
@article{77de4d9bc2444a2daa554a0cebb1747b,
title = "The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial: Rationale and design",
abstract = "A number of major clinical trials have demonstrated the clinical benefits of lowering blood pressure and have indicated that a majority of patients with hypertension will require more than one drug to achieve optimal blood pressure control. However, there is little data showing which antihypertensive combination best protects patients from cardiovascular events and which best achieves the target blood pressure with the fewest adverse events. The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial is the first large-scale investigator-initiated multicenter study with a prospective, randomized, open, blinded endpoint evaluation (PROBE) design to directly compare cardiovascular mortality and morbidity, incidence of adverse drug reaction, and degree of blood pressure reduction in Japanese hypertensive patients for a combination of angiotensin receptor blockers, β-blockers or thiazide diuretics in addition to a calcium antagonist, benidipine hydrochloride, with a response-dependent dose titration scheme. The COPE trial is being conducted with the cooperation of more than 100 centers and clinics in Japan and involves 3,000 patients, who will be followed for 3 years. Eligible patients are being enrolled from May 2003 until May 2006. Results from the COPE trial should provide new evidence for selecting optimal combination therapies for hypertensive patients.",
keywords = "Benidipine, Combination therapy, Hypertension, Multicenter clinical trial, PROBE (prospestive, randomized, open, blinded endpoint evaluation)",
author = "Toshio Ogihara and Masunori Matsuzaki and Hiroaki Matsuoka and Kazuaki Shimamoto and Kazuyuki Shimada and Hiromi Rakugi and Seiji Umemoto and Akira Kamiya and Norihiro Suzuki and Hiroo Kumagai and Yasuo Ohashi and Shuichi Takishita and Keishi Abe and Takao Saruta and K. Kikuchi and S. Itoh and H. Suzuki and T. Fujita and J. Higaki and T. Etoh and C. Tei and S. Nogawa and T. Yoshikawa and K. Yumura and K. Utsunomiya and K. Kario and K. Kitagawa and H. Makino and M. Matsumoto and K. Hayashi and M. Kawana and M. Fujishima and K. Otsuka and K. Tanabe",
year = "2005",
month = "4",
doi = "10.1291/hypres.28.331",
language = "English",
volume = "28",
pages = "331--338",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial

T2 - Rationale and design

AU - Ogihara, Toshio

AU - Matsuzaki, Masunori

AU - Matsuoka, Hiroaki

AU - Shimamoto, Kazuaki

AU - Shimada, Kazuyuki

AU - Rakugi, Hiromi

AU - Umemoto, Seiji

AU - Kamiya, Akira

AU - Suzuki, Norihiro

AU - Kumagai, Hiroo

AU - Ohashi, Yasuo

AU - Takishita, Shuichi

AU - Abe, Keishi

AU - Saruta, Takao

AU - Kikuchi, K.

AU - Itoh, S.

AU - Suzuki, H.

AU - Fujita, T.

AU - Higaki, J.

AU - Etoh, T.

AU - Tei, C.

AU - Nogawa, S.

AU - Yoshikawa, T.

AU - Yumura, K.

AU - Utsunomiya, K.

AU - Kario, K.

AU - Kitagawa, K.

AU - Makino, H.

AU - Matsumoto, M.

AU - Hayashi, K.

AU - Kawana, M.

AU - Fujishima, M.

AU - Otsuka, K.

AU - Tanabe, K.

PY - 2005/4

Y1 - 2005/4

N2 - A number of major clinical trials have demonstrated the clinical benefits of lowering blood pressure and have indicated that a majority of patients with hypertension will require more than one drug to achieve optimal blood pressure control. However, there is little data showing which antihypertensive combination best protects patients from cardiovascular events and which best achieves the target blood pressure with the fewest adverse events. The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial is the first large-scale investigator-initiated multicenter study with a prospective, randomized, open, blinded endpoint evaluation (PROBE) design to directly compare cardiovascular mortality and morbidity, incidence of adverse drug reaction, and degree of blood pressure reduction in Japanese hypertensive patients for a combination of angiotensin receptor blockers, β-blockers or thiazide diuretics in addition to a calcium antagonist, benidipine hydrochloride, with a response-dependent dose titration scheme. The COPE trial is being conducted with the cooperation of more than 100 centers and clinics in Japan and involves 3,000 patients, who will be followed for 3 years. Eligible patients are being enrolled from May 2003 until May 2006. Results from the COPE trial should provide new evidence for selecting optimal combination therapies for hypertensive patients.

AB - A number of major clinical trials have demonstrated the clinical benefits of lowering blood pressure and have indicated that a majority of patients with hypertension will require more than one drug to achieve optimal blood pressure control. However, there is little data showing which antihypertensive combination best protects patients from cardiovascular events and which best achieves the target blood pressure with the fewest adverse events. The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial is the first large-scale investigator-initiated multicenter study with a prospective, randomized, open, blinded endpoint evaluation (PROBE) design to directly compare cardiovascular mortality and morbidity, incidence of adverse drug reaction, and degree of blood pressure reduction in Japanese hypertensive patients for a combination of angiotensin receptor blockers, β-blockers or thiazide diuretics in addition to a calcium antagonist, benidipine hydrochloride, with a response-dependent dose titration scheme. The COPE trial is being conducted with the cooperation of more than 100 centers and clinics in Japan and involves 3,000 patients, who will be followed for 3 years. Eligible patients are being enrolled from May 2003 until May 2006. Results from the COPE trial should provide new evidence for selecting optimal combination therapies for hypertensive patients.

KW - Benidipine

KW - Combination therapy

KW - Hypertension

KW - Multicenter clinical trial

KW - PROBE (prospestive, randomized, open, blinded endpoint evaluation)

UR - http://www.scopus.com/inward/record.url?scp=21244464728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244464728&partnerID=8YFLogxK

U2 - 10.1291/hypres.28.331

DO - 10.1291/hypres.28.331

M3 - Article

VL - 28

SP - 331

EP - 338

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 4

ER -